The active compounds in kratom, such as mitragynine and 7-hydroxymitragynine, interact with opioid receptors in the brain, leading to similar risks as opioids. These include severe withdrawal symptoms, dependency, and potential for overdose. The unregulated nature of kratom products further increases these risks due to inconsistent potency and possible contamination. Schedule I classification is essential to control these dangers effectively